



5 December 2023

cyclopharm
medica
technegas

The Manager
Company Announcements Office
Australian Securities Exchange Limited
20 Bridge Street
Sydney NSW 2000

Cyclopharm Ltd
ABN 74 116 931 250
Unit 4, 1 The Crescent
Kingsgrove NSW 2208 Australia
T 61 2 9541 0411
F 61 2 9543 0960
www.cyclopharm.com.au

CYCLOPHARM SIGNS FIRST USA CONTRACT FOR TECHNEGAS®

Cyclopharm Limited (ASX: CYC) is pleased to announce that Duke University Hospital has signed the first commercial contract for the use of Technegas in the United States. Following the approval of Technegas by the United States Food and Drug Administration (USFDA) on 29 September 2023, this agreement signifies a major milestone for the company.

Duke University Hospital (Duke), located in Durham, North Carolina, is part of the larger Duke University Health System. It is a renowned academic medical centre known for its high-quality patient care, research and medical education. The hospital is affiliated with Duke University and serves as a teaching hospital for the Duke University School of Medicine. Duke University Hospital is consistently ranked among the top medical centres in the United States offering a wide range of specialties. Duke was one of ten locations in the USA that participated in the Company's recent clinical trial that was submitted as part of the New Drug Application (NDA) for Technegas.

Cyclopharm's Managing Director James McBrayer said, "I am thrilled that Duke University Hospital, a globally respected centre of healthcare excellence, innovation and a recent clinical trial site for Technegas, will be among the first to offer Technegas to their referring physicians and patients." Mr McBrayer went on to confirm that "the implementation of Technegas at Duke will be on full commercial terms as previously communicated to the market and will be leveraging off Technegas' wide indication for use¹ approved by the USFDA".

- ENDS -

This ASX announcement was approved and authorised for release by James McBrayer, Managing Director, CEO and Company Secretary.

For more information, please contact:

Mr James McBrayer
Managing Director, CEO and Company Secretary
Cyclopharm Limited
T: +61 (02) 9541 0411

¹ TECHNEGAS, when used with sodium pertechnetate Tc 99m in the Technegas Plus System, provides technetium Tc 99m-labeled carbon inhalation aerosol (Technegas Aerosol), a radioactive diagnostic agent for use in adults and pediatric patients aged 6 years and older for visualization of pulmonary ventilation and evaluation of pulmonary embolism when paired with perfusion imaging.

Cyclopharm Limited

Cyclopharm is an ASX Listed radiopharmaceutical company servicing the global medical community. The Company's mission is to provide nuclear medicine and other clinicians with the ability to improve patient care outcomes. Cyclopharm achieves this objective primarily through the provision of its core radiopharmaceutical product, Technegas® used in functional lung ventilation imaging.

Technegas®

The Technegas® technology is a structured ultra-fine dispersion of radioactive labelled carbon, produced by using dried Technetium-99m in a carbon crucible, micro furnaced for a few seconds at around 2,700° C. The resultant gas like substance is inhaled by the patient (lung ventilation) via a breathing apparatus, which then allows multiple views and tomography imaging under a gamma or single photon emission computed tomography (SPECT) camera for evaluating functional ventilation imaging. Historically used in the diagnosis of pulmonary embolism, Technegas®, together with advancements in complementary technology to multimodality imaging and analytical software, is being used in other disease states to include COPD, asthma, pulmonary hypertension, Long COVID and certain interventional applications to include lobectomies in lung cancer and lung volume reduction surgery.

For personal use only